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The ability to study HIV-1-specific cytotoxic T cell (CTL) clones in models in vitro or to expand them for immunotherapeutic use is
limited by the technical difficulty of propagating these cells. The factors that determine the survival and proliferation of the cells are
incompletely understood and could include cytokines provided from feeder cells or serum. We therefore investigated the effects of adding
two cytokines reported to have effects on T cell proliferation and function, interleukin (IL)-7 and IL-15. Four HIV-1-specific clones derived
from infected persons were cultured under standard conditions with IL-2 compared to IL-7 or IL-15 alone or in combination with IL-2.
Proliferation and survival, as reflected by cell numbers after stimulation, were poorly supported by IL-7 or IL-15 alone, and these cytokines
appeared to provide no additional benefit when added to IL-2. Similarly, these cytokines alone did not support the functional status of these
cells as measured by chromium release assays with peptide-pulsed target cells. Addition of IL-7 or IL-15 to IL-2 did not augment function of
the cells. These data suggest that supplementing CTL cultures with these cytokines does not provide improvement of cell growth or function.
D 2004 Elsevier Inc. All rights reserved.Keywords: HIV-1; Cytotoxic T lymphocyte; IL-7; IL-15Introduction
CD8+ HIV-1-specific cytotoxic T cells (CTLs) are be-
lieved to play an important protective role in immunopatho-
genesis (reviewed in (Yang and Walker, 1997)) and
therefore have been a focus in vaccine design and immu-
notherapeutics. Recent CD8-depletion experiments in mac-
aques have underscored the effector function these cells play
in suppressing viral replication (Jin et al., 1999; Matano et
al., 1998; Schmitz et al., 1999), although early attempts at
ex vivo expansion of autologous HIV-1-specific CTL and
reinfusion into infected persons have met with limited
success (Brodie et al., 1999, 2000; Koenig et al., 1995;
Lieberman et al., 1997; McKinney et al., 1999).0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2004.04.036
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Medical Center, 10833 LeConte Avenue, Los Angeles, CA 90095. Fax: +1-
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E-mail address: oyang@mednet.ucla.edu (O.O. Yang).We (Yang et al., 1996, 1997a, 1997b, 2002) and others
(Baalen et al., 2002; Buseyne et al., 1996; Schutten et al.,
2001; Shankar et al., 1998, 1999; Van Baalen et al., 1998)
have therefore been interested in evaluating the determi-
nants of CTL antiviral function in controlled systems with
acutely HIV-1-infected target cells. To manipulate and study
factors such as CTL epitope specificity, lytic function,
cytokine production, viral sequence and accessory gene
function, and infection kinetics, highly defined in vitro
models utilizing CTL clones are crucial. Such issues are
difficult or impossible to study in vivo, where correlative
data, at best, are obtainable.
A significant technical barrier to such work, however, is
the difficulty of propagating CTL clones. Standard method-
ology involves providing a T cell receptor signal in the
presence of feeder mononuclear cells and interleukin (IL)-2
in medium with serum (Walker et al., 1989), and the factors
that determine the survival and proliferation of the cells are
incompletely understood. Working with primary CTL
clones is a challenging technical barrier as these cells tend
to exist in a terminally differentiated state in vivo probably
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infection (recently reviewed in (Appay and Rowland-Jones,
2002; Van Baarle et al., 2002)) and survive poorly once
isolated in vitro.
We therefore evaluated the ability of two cytokines
known to have effects on T cell development, survival,
and function: interleukin IL-7 and IL-15. Because the
factors provided by feeder cells and serum influencing the
ability of CTL to proliferate are poorly defined, these
cytokines were tested as potential candidates for increasing
the efficiency of CTL propagation.Fig. 1. Growth of HIV-1-specific CTL clones cultured with IL-2, IL-7, and
IL-15. Four clones were restimulated in parallel in medium containing IL-2
at 50 U/ml, IL-7 at 0.3 ng/ml (low) or 1 ng/ml (high), IL-15 at 0.3 ng/ml
(low) or 1 ng/ml (high), or combinations of IL-2 with IL-7 or IL-15.
Restimulation was performed with anti-CD3 and irradiated allogeneic
feeder PBMC, and cell concentrations were monitored after 1 week. Under
the standard condition of IL-2 alone, the clones proliferated to a mean
concentration of 5.7  105/ml, standard deviation 1.2  105. Plotted here
are the ratios of cell concentration under the various conditions versus IL-2
alone. Error bars represent one standard deviation. These results were
repeated and confirmed using two additional CTL clones with IL-7 and IL-
15 (known to be bioactive in a human thymocyte culture system) from other
sources (data not shown).Results
Neither IL-7 nor IL-15 appears to augment proliferation of
HIV-1-specific CTL clones in culture
Four HIV-1-specific CTL clones were restimulated
using anti-CD3 antibody, irradiated allogeneic feeder
PBMC, and various cytokines (Fig. 1). A standard condi-
tion, utilizing 50 U/ml of IL-2, served as a comparison for
tests of IL-7 and IL-15. Either IL-7 or IL-15 alone at
‘‘low’’ (0.3 ng/ml z 600 U/ml) or ‘‘high’’ concentrations
(1 ng/ml z 2000 U/ml) did not support growth as well as
IL-2, yielding cell numbers of about 40–50% by compar-
ison. When these concentrations of IL-7 and IL-15 were
added to IL-2, cell numbers after expansion were not
significantly changed compared to IL-2 alone, ranging
from about 100% to 120% by comparison. These data
indicated that neither IL-7 nor IL-15 significantly boosted
the proliferation or survival of the CTL clones, over that
of IL-2 alone, whether given alone or in conjunction with
IL-2.
Neither IL-7 nor IL-15 appears to augment lytic function of
HIV-1-specific CTL clones in culture
The CTLs grown under the above conditions were also
compared for their lytic capacity by chromium release
assays (Fig. 2). The killing capacity of these clones was
suboptimal at baseline in culture with IL-2 alone (about
50% specific lysis). Culturing with IL-7 alone resulted in a
relative loss of killing capacity on a per-cell basis (about
40% that of IL-2 alone). There appeared to be a dose-
dependent trend for increased cytolytic activity by IL-15
alone in comparison to IL-7, although at the higher dose (1
ng/ml z 2000 U/ml), killing was still about 75% the level of
that with IL-2 alone. Combining either IL-7 or IL-15 with
IL-2 perhaps slightly increased the killing capacity of the
cultured CTL to about 105–110% of that with IL-2 alone,
although the increases were not statistically significant.
Overall, these data suggested that IL-7 and IL-15 were
inferior or of minimal benefit compared to IL-2 alone in
preserving or augmenting the cytolytic function of CTL
clones.
Fig. 2. Cytolytic activity of HIV-1-specific CTL clones cultured with IL-2,
IL-7, and IL-15. Four clones were restimulated as described in Fig. 1.
Killing of autologous EBV-transformed B cells pulsed with appropriate
peptides was measured by chromium release assay after 1 week. Under the
standard condition of IL-2 alone, the clones killed their target cells (effector
to target cell ratio of 5:1) at a mean of 50.5% specific lysis, standard
deviation 21.4%. Plotted here are the ratios of killing by cells grown under
the various conditions versus IL-2 alone. Error bars represent one standard
deviation. Killing of peptide unlabelled negative control target cells was
always <5% specific lysis. These results were repeated and confirmed using
two additional CTL clones with IL-7 and IL-15 (known to be bioactive in a
human thymocyte culture system) from other sources (data not shown).
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A major limitation of culturing HIV-1-specific CTL for
immunotherapeutic infusions and in vitro functional studies
is their expansion. Despite the fact that antiviral CTL
responses are easily detectable and fairly high frequency
in the majority of infected persons, deriving and maintaining
CTL clones are technically demanding. This may be due to
exhaustion or abnormal differentiation due to chronic turn-
over in response to persistent antigen over years of infection
as suggested by multiple studies of CTL phenotype in
chronically infected persons (Appay and Rowland-Jones,
2002; Van Baarle et al., 2002). We and others have been
interested in studying the interaction of defined CTL clones
with HIV-1 by in vitro models, and this line of investigation
has been limited in a large part by the limited availability of
CTL clones, as reflected by the relatively small number of
published studies in this area. We therefore evaluated two
cytokines reported to have effects on T cell growth and
survival to test whether they might enhance the proliferative
capacity of HIV-1-specific CTL in vitro.
The cytokine IL-7 likely has a central role in T cell
development and survival. Multiple studies suggest that IL-
7 is an important factor in the thymus from the development
from thymocyte precursors to early T cells (Conlon et al.,
1989; Fabbi et al., 1992; Hickman et al., 1990; Kim et al.,
1998; Von Freeden-Jeffry et al., 1997). Additional evidence
suggests that IL-7 continues to have modulatory effects on
mature T cells, contributing to the survival and expansion of
naive (Soares et al., 1998) and memory (Welch et al., 1989)
T cells, presumably through costimulation in conjunction
with T cell receptor signaling (Gringhuis et al., 1997). Two
reports have suggested that IL-7 might be useful in stimu-
lating and expanding HIV-1-specific T cells (Ferrari et al.,
1995; Kim et al., 1997).
IL-15 has also been reported to have effects on T cell
survival and proliferation. This cytokine is believed to share
overlapping biologic properties with IL-2, acting through
the h and g chains of the IL-2 receptor (Giri et al., 1994;
Tagaya et al., 1996) as well as through a specific IL-15
receptor a chain (Giri et al., 1995), perhaps mediating an
anti-apoptotic signal (Bulfone-Paus et al., 1997). Some
data have indicated that IL-15 may be useful in expan-
sion of CTL in SIV-infected macaques (Kanai et al., 1996)
as well as CD8+ T cells (Agostini et al., 1997) and NK/
CD4+ lymphocytes (Chehimi et al., 1997) in HIV-1-infected
subjects.
Our data, however, did not indicate that either of these
cytokines had marked effects on our ability to grow HIV-
1-specific CTL clones in culture. Neither proliferation or
survival, as reflected by cell concentrations after stimula-
tion, nor lytic capacity was significantly enhanced by IL-7
or IL-15. Use of either of these cytokines alone instead of
IL-2 resulted in lower cell numbers and decreased lytic
function. Although both IL-7 and IL-15 alone resulted in
similarly less proliferation than IL-2 alone, IL-15 some-
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fashion, perhaps due to its partial functional overlap with
IL-2.
Use of these cytokines in conjunction with IL-2 did not
appear to augment significantly either cell number or
function. There are multiple potential explanations. These
cytokines could already be provided in feeder cells or
culture medium. IL-15 is known to be produced by periph-
eral blood monocytes (Tagaya et al., 1996), while mature
dendritic cells may produce IL-7 (Sorg et al., 1998),
although thymic and bone marrow stroma are likely the
major sites of IL-7 production (Wiles et al., 1992). Another
possibility is that these cells are in a state of activation or
differentiation that is not amenable to the action of these
cytokines because HIV-1-specific CTLs are believed to be
functionally impaired due to chronic turnover or other
factor(s). Still another possibility is that the action of these
cytokines on CTL is redundant with that of IL-2, particu-
larly in the case of IL-15.
In summary, culturing HIV-1-specific CTL clones with
IL-7 or IL-15 was inferior to using IL-2 alone, and the
addition of these cytokines to IL-2 did not provide any
significant additional advantage. There are several possible
explanations why these cytokines did not augment the
numbers and function of these cells as reported in other
systems, and these possibilities are not mutually exclusive.
Our data therefore do not support the use of these cytokines
as a means to improve in vitro culture of these cells,
although IL-7 and IL-15 may have other activities such as
boosting T cell production and memory precursor T cell
survival in vivo.Materials and methods
CTL clones
CTL clones were derived by limiting dilution cloning
from PBMC of HIV-1-infected persons and maintained as
previously described (Walker et al., 1989). Clone 68A62
(the kind gift of Dr. Bruce D. Walker) recognized the HLA
A2-restricted epitope ILKEPVHGV (RT aa 309–317) and
was isolated by blind limiting dilution cloning from unex-
panded PBMC. Clones 0001/10.7 and 0001/10.18 were
independently derived clones recognizing the HLA A2-
restricted epitope SLYNTVATL (Gag p17 aa 77–85), each
isolated by limiting dilution cloning from a CTL-enriched
line produced by immunomagnetic capture of IFN-g-pro-
ducing cells (as per manufacturer’s instructions, MACS,
Miltenyi). Clone 0010/5.10P was isolated from a CTL-
enriched line produced by immunomagnetic capture of
IFN-g-producing cells recognizing an HLA A25-restricted
epitope within the peptide sequence FTIPSINNETPGIRY
(NIH AIDS Research and Reference Repository catalogue #
5532, RT aa 130–144). Sequence numbers are given rela-
tive to HXB2.Cytokines
Recombinant human IL-2 was obtained from the NIH
AIDS Research and Reference Repository. Recombinant
human IL-7 and IL-15 were purchased from Biotechdiag-
nostics, L.L.C. IL-7 and IL-15 were each certified to be >98%
pure by SDS-PAGE and HPLC, with a specific activity of
>2  106 units/mg. For confirmation, the experiments were
also repeated with lots of IL-7 from Immunex (Seattle, WA)
and IL-15 from Amgen (Thousand Oaks, CA) that have been
shown to be bioactive in multiple human thymic culture
studies (Gurney et al., 2002; Pedroza-Martins et al., 2002).
CTL restimulation
CTLs that had not been stimulated for at least 7 days were
restimulated with the anti-CD3 antibody 12F6 at 0.1 Ag/ml,
irradiated allogeneic feeder PBMC, and the indicated cyto-
kine(s) in RPMI 1640 (Sigma) supplemented with 10% heat-
inactivated fetal calf serum (Hyclone), penicillin-streptomy-
cin, and L-glutamine as previously described (Yang et al.,
1996, 1997a). The cells were fed with fresh medium con-
taining the appropriate cytokine(s) after 3 or 4 days, and then
counted and tested in chromium release assays after 7 days.
Chromium release assays
Autologous EBV-transformed B cells served as targets
for the CTL clones in standard chromium release assays
performed as previously described (Yang et al., 1996).
Briefly, the target cells were labeled for 1 h with 51Cr with
or without the appropriate peptide at 10 Ag/ml, followed by
washing and plating in a 96-well U-bottom plate at 104
cells/well. The CTL clones were then added at 5  104
cells/well in a total volume of 200 Al for a 4-h incubation.
Spontaneous and maximal lysis wells utilized medium
without CTL and 2.5% Triton x-100 (Sigma), respectively.
Supernatants were then harvested to Lumaplates (Packard)
and chromium counts were determined by microscintillation
counting (Microbeta 1450, Wallac). Percent specific lysis
was calculated as: 100  (experimental release  sponta-
neous release)/(maximal release  spontaneous release).Acknowledgments
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